-

10:57:15 PM

TAK Stock News

TAK - Takeda Pharmaceutical Co

06/27/22 6:00 AM

NYSE, Nasdaq : TAK, ARWR

clinical trial

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Takeda and Arrowhead Pharmaceuticals Inc. today announced that results from a Phase 2 clinical study of investigational fazirsiran for the treatment of liver disease associated with alpha-1 antitrypsin deficiency were recently published in the...

RHEA-AI

neutral

06/22/22 6:55 AM

NYSE : TAK

Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

Takeda today announced that it has signed a 15- year lease with BioMed Realty for approximately 600,000 square feet of research and development and office space to be built at 585 Third Street in Kendall Square. The agreement with BioMed Realty further expands Takeda’ s presence in Kendall Square, a hub for life sciences, and is part of the company's long-term...

RHEA-AI

positive

06/09/22 4:30 AM

NYSE : TAK

clinical trial

Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial

In Long-Term Exploratory Analysis, TAK -003 Prevented 84% of Hospitalizations and 61% of Symptomatic Dengue Illness Overall, with No Identified Important Safety Risks Results Through 4.5 Years Conclude the Evaluation of the Primary Two-Dose Series of TAK -003 TAK -003 is Currently Undergoing Regulatory Review for Potential Licensure in Both the...

RHEA-AI

very negative

05/31/22 8:00 AM

NYSE : TAK

Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

Positive Results from the Phase 3 PARADIGM Study in Japanese Patients with Colorectal Cancer to be Presented During the Plenary Session at ASCO, in Collaboration with Amgen Overall Survival Data to be Presented during Oral Sessions at both ASCO and EHA from the Phase 3 ECHELON-1 Trial in Patients with Previously Untreated Advanced Hodgkin Lymphoma, in...

RHEA-AI

very positive

05/31/22 3:56 AM

NYSE, Nasdaq : TAK, MRNA

covid-19

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Takeda announced to transfer...

RHEA-AI

very positive

05/31/22 3:40 AM

Nasdaq, NYSE : MRNA, TAK

covid-19

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for Spikevax TM from August 1, 2022 Companies concluded memorandum of understanding that Takeda will continue to provide

RHEA-AI

very positive

05/26/22 5:25 PM

NYSE, Nasdaq : TAK, SGEN

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

Takeda Pharmaceutical Company Limited and Seagen Inc., today announced that overall survival data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS ® plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology Annual Meeting on Friday, June 3, 2022,...

RHEA-AI

positive

05/11/22 2:15 AM

NYSE : TAK

Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

Takeda president and chief executive officer, Christophe Weber, commented:“ We are pleased to report another year of strong performance, driven by our growth products. Takeda chief financial officer, Costa Saroukos, commented:“ Takeda’ s strong FY2021 performance against our management guidance provides a solid foundation for our FY2022 outlook for continued...

RHEA-AI

neutral

04/26/22 8:00 AM

NYSE : TAK

Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories

Takeda today announced that the International Society for Pharmaceutical Engineering has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards.

RHEA-AI

neutral

04/22/22 8:00 AM

NYSE : TAK

Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

Data Include Exploratory Analysis Showing LIVTENCITY Treated Patients With Post-Transplant Cytomegalovirus Infections/Disease Had Reductions in Hospitalizations and Length of Hospital Stay Compared to Those Treated With Conventional Antiviral Therapies 1* Post-Hoc Analyses by Subgroup Showed Shorter Time to First Confirmed CMV DNA Level Less...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next